Artemether

Artemether is an artemisinin-derivative antimalarial most commonly formulated in fixed-dose combination with lumefantrine, the WHO-recommended first-line therapy for uncomplicated Plasmodium falciparum malaria. Simson Pharma's Artemether reference standard and impurities support QC across this globally vital antimalarial combination.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Artemether Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.

Pharmaceutical Reference Standards / Impurity Standards

Artemether
Artemether Related Compound A
Artemether Impurity 3
Artemether Related Compound B
Artemisinin
Anhydro Dihydro Artemisinin
Artemether EP Impurity A
Artemether EP Impurity C
Artemisitene
Dihydro Artemisinin Dimer
Dihydroartemisinin Impurity H
Artemether impurity B
9-epi-Artemisinin
Deoxydihydroartemisinin
Dihydroartemisinin
Artemether Succinate Dimer
Diphenylacetic Acid
Diphenylacetyl Chloride
Dihydroartemisinin Impurity I
Artemisinin Impurity 1
3-Hydroxy Deoxy Dihydro Artemisinin
Artemether EP Impurity C (MIXTURE OF ISOMERS)
2-(4-methyl-2-oxo-3-(3-oxobutyl)cyclohexyl)propanal
2-((4R)-4-Methyl-2-oxo-3-(3-oxobutyl)cyclohexyl)propanal
Artemether Furoisochromen Impurity
Dihydro Artemisinic Acid
(11S)-Dihydroartemisinic Acid
Artemether impurity 1
Artemether impurity 2
Artemisinin Impurity 3

Metabolites

Dihydroartemisinin-12-alpha-O-beta-D-Glucuronide

Isotope Labelled Compounds

Dihydroartemisinin D3
Artemether-D3
Dihydroartemisinin-13C, D4